Investigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis

Pub Date : 2024-01-29 DOI:10.34172/jrip.2024.32276

Ramin Haghighi, Nasim Zaman Samghabadi, Roya Raeisi Jaski, Sonia Razmjou, Alireza Habibzadeh, Ahmad Maleki Ahmadabadi, Babak Gholamine, Mahdi Behi, Zahra Tavassoli

{"title":"Investigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis","authors":"Ramin Haghighi, Nasim Zaman Samghabadi, Roya Raeisi Jaski, Sonia Razmjou, Alireza Habibzadeh, Ahmad Maleki Ahmadabadi, Babak Gholamine, Mahdi Behi, Zahra Tavassoli","doi":"10.34172/jrip.2024.32276","DOIUrl":null,"url":null,"abstract":"Introduction: Sodium-glucose transporter 2 (SGLT-2) inhibitors induce glycosuria. Therefore, using a meta-analysis study, this study aimed to evaluate the correlation between SGLT2 inhibitor administration and urinary tract infection (UTI) risk. Materials and Methods: In this systematic review and meta-analysis, we conducted searches on Scopus, PubMed, Web of Science, Cochrane, and Google Scholar without time limitations up to October 16, 2023. Data were analyzed using STATA 14 software, and a significance level of P < 0.05 was considered. Results: The combination of 11 studies revealed that the use of SGLT2 inhibitors, when compared to glucagon-like peptide-1 (GLP-1) receptor agonists, reduced the risk of UTI (OR = 0.77; 95% CI: 0.62, 0.95) and when compared to insulin (OR = 0.74; 95% CI: 0.63, 0.87). However, the administration of SGLT2 inhibitors, when compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors (OR = 1.09; 95% CI: 0.90, 1.32), sulfonylureas (OR = 1.35; 95% CI: 0.88, 2.05), biguanide initiators (OR = 1.14; 95% CI: 1.05, 1.24), thiazolidinediones (OR = 1.19; 95% CI: 0.58, 2.44), and other antidiabetic drugs (OR = 1.20; 95% CI: 0.92, 1.57), did not increase the risk of UTI. The administration of dapagliflozin (OR = 1.51; 95% CI: 0.60, 3.81), canagliflozin (OR = 1.22; 95% CI: 0.47, 3.15), and empagliflozin (OR = 3.22; 95% CI: 2.97, 3.48) showed associations with UTI risk. Furthermore, the correlation between SGLT2 inhibitors use and UTI risk was observed in cohort studies (OR = 1.14; 95% CI: 0.98, 1.32), cross-sectional studies (OR = 0.86; 95% CI: 0.64, 1.14), in males (OR = 1; 95% CI: 0.72, 1.40), and females (OR = 1.17; 95% CI: 0.91, 1.52). Conclusion: Empagliflozin, in contrast to dapagliflozin and canagliflozin, increases the risk of UTI. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023479548) and Research Registry (UIN: reviewregistry1742) Websites","PeriodicalId":0,"journal":{"name":"","volume":"48 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jrip.2024.32276","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Sodium-glucose transporter 2 (SGLT-2) inhibitors induce glycosuria. Therefore, using a meta-analysis study, this study aimed to evaluate the correlation between SGLT2 inhibitor administration and urinary tract infection (UTI) risk. Materials and Methods: In this systematic review and meta-analysis, we conducted searches on Scopus, PubMed, Web of Science, Cochrane, and Google Scholar without time limitations up to October 16, 2023. Data were analyzed using STATA 14 software, and a significance level of P < 0.05 was considered. Results: The combination of 11 studies revealed that the use of SGLT2 inhibitors, when compared to glucagon-like peptide-1 (GLP-1) receptor agonists, reduced the risk of UTI (OR = 0.77; 95% CI: 0.62, 0.95) and when compared to insulin (OR = 0.74; 95% CI: 0.63, 0.87). However, the administration of SGLT2 inhibitors, when compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors (OR = 1.09; 95% CI: 0.90, 1.32), sulfonylureas (OR = 1.35; 95% CI: 0.88, 2.05), biguanide initiators (OR = 1.14; 95% CI: 1.05, 1.24), thiazolidinediones (OR = 1.19; 95% CI: 0.58, 2.44), and other antidiabetic drugs (OR = 1.20; 95% CI: 0.92, 1.57), did not increase the risk of UTI. The administration of dapagliflozin (OR = 1.51; 95% CI: 0.60, 3.81), canagliflozin (OR = 1.22; 95% CI: 0.47, 3.15), and empagliflozin (OR = 3.22; 95% CI: 2.97, 3.48) showed associations with UTI risk. Furthermore, the correlation between SGLT2 inhibitors use and UTI risk was observed in cohort studies (OR = 1.14; 95% CI: 0.98, 1.32), cross-sectional studies (OR = 0.86; 95% CI: 0.64, 1.14), in males (OR = 1; 95% CI: 0.72, 1.40), and females (OR = 1.17; 95% CI: 0.91, 1.52). Conclusion: Empagliflozin, in contrast to dapagliflozin and canagliflozin, increases the risk of UTI. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023479548) and Research Registry (UIN: reviewregistry1742) Websites

查看原文

调查服用 SGLT-2 抑制剂与尿路感染风险之间的关联；系统综述和荟萃分析

简介钠-葡萄糖转运体 2（SGLT-2）抑制剂会诱发糖尿。因此，本研究采用荟萃分析法，旨在评估服用 SGLT2 抑制剂与尿路感染（UTI）风险之间的相关性。材料与方法：在本系统综述和荟萃分析中，我们在Scopus、PubMed、Web of Science、Cochrane和Google Scholar上进行了检索，检索时间不受限制，截至2023年10月16日。数据使用 STATA 14 软件进行分析，显著性水平为 P <0.05。结果综合 11 项研究发现，与胰高血糖素样肽-1 (GLP-1) 受体激动剂相比，使用 SGLT2 抑制剂可降低 UTI 风险（OR = 0.77；95% CI：0.62, 0.95），与胰岛素相比（OR = 0.74；95% CI：0.63, 0.87）也是如此。然而，与二肽基肽酶-4（DPP-4）抑制剂（OR = 1.09；95% CI：0.90，1.32）、磺脲类药物（OR = 1.35；95% CI：0.88，2.05）、双胍类起始剂（OR = 1.14；95% CI：1.05，1.24）、噻唑烷二酮类（OR = 1.19；95% CI：0.58，2.44）和其他抗糖尿病药物（OR = 1.20；95% CI：0.92，1.57）不会增加 UTI 风险。服用达帕格列净（OR = 1.51；95% CI：0.60，3.81）、卡那格列净（OR = 1.22；95% CI：0.47，3.15）和恩帕格列净（OR = 3.22；95% CI：2.97，3.48）与 UTI 风险有关。此外，在队列研究（OR = 1.14；95% CI：0.98，1.32）、横断面研究（OR = 0.86；95% CI：0.64，1.14）、男性（OR = 1；95% CI：0.72，1.40）和女性（OR = 1.17；95% CI：0.91，1.52）中均观察到使用 SGLT2 抑制剂与 UTI 风险之间的相关性。结论与达帕格列净和卡格列净相比，恩帕格列净会增加UTI风险。注册：本研究根据PRISMA核对表编制，其研究方案已在PROSPERO（CRD42023479548）和研究注册中心（UIN：reviewregistry1742）网站注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文